Dr. Keefe’s research is primarily devoted to understanding cognitive dysfunction and its treatment in patients with schizophrenia and related disorders, including those at high risk for developing schizophrenia. He has had a leadership role for cognitive methods in several large NIMH studies, including the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE), Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS), Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) and Treatment and Evaluation Network for Trials in Schizophrenia (TENETS) projects. He is a co-principal investigator and Director of the Neurocognitive Core for the Translational and Clinical Research Schizophrenia Project at the Institute of Mental Health in Singapore, aiming to determine which cognitive and clinical factors best predict psychotic disorders in young high-risk subjects. He is President of the International Society for Central Nervous System Clinical Trials and Methodology and the Founder and CEO of NeuroCog Trials, Inc., a cognition services company for the pharmaceutical industry.